{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=REGENXBIO+Inc.",
    "query": {
      "sponsor": "REGENXBIO Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=REGENXBIO+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:19:48.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06942520",
      "title": "Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "RGX-314 Dose 1",
          "type": "GENETIC"
        },
        {
          "name": "RGX-314 Dose 2",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept (2.0 mg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "Sierra Eye Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "25 Years to 89 Years"
      },
      "enrollment_count": 18,
      "start_date": "2025-03-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06942520"
    },
    {
      "nct_id": "NCT04571970",
      "title": "RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis Type II (MPS II)"
      ],
      "interventions": [
        {
          "name": "RGX-121",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "5 Years to 17 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2021-03-11",
      "completion_date": "2024-05-23",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04571970"
    },
    {
      "nct_id": "NCT05683379",
      "title": "AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AAV8 DetectCDx",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "0 Years to 25 Years · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2022-12-20",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05683379"
    },
    {
      "nct_id": "NCT04704921",
      "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "AMD",
        "nAMD",
        "Wet Age-related Macular Degeneration",
        "wAMD",
        "Wet AMD",
        "CNV",
        "Neovascular AMD",
        "Neovascular Age-related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "ABBV-RGX-314",
          "type": "GENETIC"
        },
        {
          "name": "Ranibizumab (LUCENTIS®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 671,
      "start_date": "2020-12-29",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 89,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704921"
    },
    {
      "nct_id": "NCT03566043",
      "title": "CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis Type II (MPS II)"
      ],
      "interventions": [
        {
          "name": "RGX-121",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "4 Months to 5 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2018-09-27",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 4,
      "location_summary": "Oakland, California • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03566043"
    },
    {
      "nct_id": "NCT02651675",
      "title": "A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia (HoFH)"
      ],
      "interventions": [
        {
          "name": "AAV directed hLDLR gene therapy",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-03",
      "completion_date": "2020-11-27",
      "has_results": true,
      "last_update_posted_date": "2023-07-13",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 5,
      "location_summary": "Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02651675"
    },
    {
      "nct_id": "NCT04591834",
      "title": "Mucopolysaccharidosis Type II Observational",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucopolysaccharidosis II"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "8 Years",
        "sex": "MALE",
        "summary": "1 Month to 8 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2022-03",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2022-10-10",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04591834"
    },
    {
      "nct_id": "NCT04148001",
      "title": "Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia (HoFH)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-12-04",
      "completion_date": "2020-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 1,
      "location_summary": "Boca Raton, Florida",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04148001"
    },
    {
      "nct_id": "NCT03529786",
      "title": "Mucopolysaccharidosis Type II Natural History",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucopolysaccharidosis II"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 36,
      "start_date": "2017-09-27",
      "completion_date": "2022-03-22",
      "has_results": false,
      "last_update_posted_date": "2022-04-26",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529786"
    },
    {
      "nct_id": "NCT07236606",
      "title": "RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MPS II",
        "Hunter Syndrome (MPS II)"
      ],
      "interventions": [
        {
          "name": "RGX-121-3102",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "4 Months to 5 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2025-11-25",
      "completion_date": "2031-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-07-23T14:19:48.368Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07236606"
    }
  ]
}